Clinical Trial Update: Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. [Phase 1, Phase 2]

View source ↗

Summary

This completed Phase 1/2 study evaluated a combination of lenalidomide, bendamustine, and rituximab as first-line therapy in patients over 65 with mantle cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)
• Rituxan (rituximab)
• Treanda (Bendamustine)

Snippet

Sponsor: Lund University Hospital | Conditions: Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED